1. Media & Marketing

Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

Written by Posted on Less than 0 min read

Cut through the steamy summer haze with our refreshing selection of articles and insights. In this issue:

  • CVS disassociates itself from its chain pharmacy association
  • Payers are paying attention to ICER
  • Benefits of the biosimilar boom
  • A fantastic takedown of health insurance deductibles

Plus, I join the Advisory Board of Alto Pharmacy.

P.S. Join my nearly 30,000 (!) LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 14,700 followers.

Join me next week for my new live video webinar, Specialty Drugs Update: Trends, Controversies, and Outlook, on July 29, 2022, from 12:00 p.m. to 1:30 p.m. ET. I’ll cover market trends, payer strategies, channel developments, key trends that will help you plan for the future, and more. Click here for details and registration info.

Read more »

Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Retail Ecosystem

The Consolidated Drug Channel and Cash-Pay Drugs: My Podcast with a16z’s Julie Yoo

I recently joined Julie Yoo on Bio Eats World, a podcast from legendary venture capital firm Andreessen Horowitz (also known as “a16z”). Julie is a General Partner at Andreessen Horowitz. We chatted about the current state of the U.S. drug channel, the roles and controversies around pharmacy benefit managers (PBMs), GoodRx, Mark Cuban’s cost-plus pharmacy, […]
2 min read
0
  1. Media & Marketing

A Clear Path to Education Affordability Requires Meeting Patients Where They Are

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. Kristina shares the story of a patient who cut pills in half to extend her prescriptions. Unfortunately, this patient didn’t know about manufacturer affordability programs. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, […]
2 min read
0
  1. Media & Marketing

Copay Accumulator and Maximizer Update: Adoption Plateaus as Insurers Battle Patients Over Copay Support

Is the gold rush in copay accumulators and maximizers slowing down? Our latest update finds that for 2022, about 40% of commercial lives have adopted these benefit designs. Accumulator adoption has plateaued, while maximizer use has overtaken accumulators. Patients who take a single-source, brand-name specialty drug for autoimmune conditions, multiple sclerosis, and oncology increasingly face […]
2 min read
0
  1. Data & Insights

The Top Pharmacy Benefit Managers of 2021: The Big Get Even Bigger (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from April 2022. The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute’s latest estimates of pharmacy benefit manager (PBM) market […]
2 min read
0
  1. Media & Marketing

The Top Indicators That a Hub Launch Will Succeed: Discovery and Partnership

Today’s guest post comes from ConnectiveRx’s Lauren Cole, Senior VP of Launch Excellence at ConnectiveRx. Lauren outlines key success factors when transitioning or launching a patient hub. To learn more, join Lauren on April 4th at 1:00 p.m. ET for a free online panel discussion: Lessons from the Edge—Six Things That Can Make a Hub […]
2 min read
0
  1. Media & Marketing

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 11, 2022, Drug Channels Institute will release The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our thirteenth edition— remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. We are providing you with the opportunity to preorder this thoroughly updated and revised […]
2 min read
0
  1. Trends & External Forces

Digital as a Disguise: Beware the Illusion of an Automated Hub Experience

Today’s guest post comes from Rebecca Cotton, Executive Director of Strategy & Product Innovation at Cardinal Health™ Sonexus™ Access and Patient Support Rebecca discusses the essential features biopharmaceutical manufacturers should seek in a digital hub that will help patients get their therapies faster. She argues that the most effective hub balances automation with the still-relevant […]
2 min read
0
  1. Media & Marketing

Four Ways for Field Teams to Tackle Drug Utilization Management and Optimize Patient Access

Today’s guest post comes from Patrick Leary, Chief Commercial Officer at Phil, Inc. Patrick describes how barriers to medication access affect manufacturers and patients. He offers four tactics that can help field teams unlock coverage for patients. To learn more about Phil’s access and commercialization solutions, download their free whitepaper, Modernize the Patient Access Experience: […]
< 1 min read
0
  1. Department: HBC

Exclusive: Five Pharmacy Chains and PBMs Dominate 2022’s Still-Booming 340B Contract Pharmacy Market

Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—now act as contract pharmacies for the hospitals and other healthcare providers that participate in the 340B program. Over […]
2 min read
0
  1. Data & Insights

Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook (NEW Live Video Webinar)

Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for a new video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook This event will be broadcast live on Friday, March 31, 2023, from 12:00 p.m. to 1:30 p.m. ET. This […]
4 min read
0
  1. Trends & External Forces

Small Pharmacies Walk Away from Medicare Part D’s 2023 Preferred Networks

In yesterday’s post, I highlighted the largest pharmacy chains that will participate in the 2023 Medicare Part D prescription drug plans (PDP). Today, I update our annual analyses of how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As you […]
2 min read
0
  1. Trends & External Forces

Value-Based Care Summit

Value-Based Care Summit Accelerating Healthcare’s Shift in the Move from Volume to Value In-Person Event January 26-27, 2023 View Original Article Health & Wellness Predictions and Forecasts Data & Insights Drug Channels Member since December 11, 2020 Loading + Follow Following Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution […]
< 1 min read
0
  1. Technology & Innovation

Technology’s New Approach: One Gateway to Deliver Comprehensive Patient Support Services

Today’s guest post comes from Derek Berven, Senior Director of Software Engineering at AssistRx. Derek explains how to streamline patient support services with a modular, scalable technology solution. He then discusses Advanced Gateway, a technology that integrates patient, provider, and manufacturer services. Click here to learn more about how AssistRx’s Advanced Gateway can impact patient […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, December 2022: Vertical Integration Updated, Walgreens vs. Pharmacy, Cash-Pay Rx, Curing 340B, and Deductible Season

Whew. It was quite a year—one filled with big deals, big news, and big legislation. Drug Channels also had a big 2022. We now have 35,000 LinkedIn followers, almost 25,000 email subscribers, and nearly 16,000 Twitter followers. Thank you, dear readers, for welcoming me into your inboxes and browsers each week. I’ve had a blast […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s PAP – Patient Assistance & Access Programs Part of Access USA

Informa Connect’s PAP – Patient Assistance & Access Programs March 20-22, 2023, Philadelphia Marriott Downtown www.informaconnect/pap Exclusive Offer – Be sure to use your exclusive promocode 23DCPAP10 to save 10% off* your registration. The last thing a patient should worry about is access to care. With growing demand for patient assistance, accelerating prescription access and […]
3 min read
0
  1. Data & Insights

Five Surprising Facts About GoodRx and the Discount Card Market (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from October 2022. Last month, IQVIA quietly released a fascinating new report on discount cards. (Link below.) The research was sponsored by the Association for Accessible Medicines […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, June 2023: Humira Price War and Mark Cuban, Formulary Exclusions, Oncology Drug Benefits, and Our Wonderful Healthcare System

Happy 247st birthday, America! Before you launch your July 4 festivities, Drug Channels offers some fireworks of our own: My $0.02 on the Humira price war—and the role of cost-plus pharmacy pricing Fresh evidence that formulary exclusions hurt patients Disturbing oncology drug benefit management Plus, an entertaining explanation of why the U.S. healthcare system is […]
< 1 min read
0
  1. Trends & External Forces

Drug Channels Outlook 2023 (NEW Live Video Webinar)

Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for a new live video webinar: Drug Channels Outlook 2023 Friday, December 16, 2022 12:00 p.m. to 1:30 p.m. ET. This page describes the event and explains how to purchase a registration to the […]
3 min read
0
  1. Channel: Grocery

The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards

A few weeks ago, GoodRx surprised investors with the unpleasant news that a major grocery chain had stopped accepting its discount card for an unspecified number of prescriptions. As I explain below, the unnamed chain appears to be Kroger—the sixth-largest U.S. pharmacy. What’s more, GoodRx disclosed that Kroger accounts for an unexpected one-quarter of its […]
2 min read
0
5
  1. Media & Marketing

How Payers Are Reacting to Insulin Price Changes

Today’s guest post comes from Nicole Mayer, Senior Analyst at MMIT. Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products. She also discusses MMIT’s […]
2 min read
0
Next